Trial Profile
Multicenter, Randomized, Non-comparative, Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Trabectedin (Primary) ; Carboplatin
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2019 Status changed from active, no longer recruiting to completed.
- 20 Sep 2019 Results published in the British Journal of Cancer
- 24 Oct 2018 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.